Parkinson’s disease (PD), the second-most common neurodegenerative disease, is characterized by motor and nonmotor symptoms. PD is often misdiagnosed; inappropriate treatment due to misdiagnosis has ...

DUBLIN--(BUSINESS WIRE)--GE Healthcare today presented the results of a randomised controlled study analyzing the effect of DaTSCAN™ (Ioflupane I 123 Injection) SPECT imaging in a group of adult ...

January 17, 2011 — GE Healthcare has announced Food and Drug Administration (FDA) approval of ioflupane iodine-123 injection (DaTscan), a contrast agent for use with single-photon emission computed ...

DaTscan is a radiopharmaceutical indicated for striatal dopamine transporter visualization using single photon emission computed tomography (SPECT) brain imaging to assist in the evaluation of adult ...

First patient dosed in Phase III clinical trial for PET radiopharmaceutical Next stage clinical study also proceeding for SPECT radiopharmaceutical Both imaging agents aim to assist in the evaluation ...

The FDA has approved DaTscan (Ioflupane I 123 Injection, from GE Healthcare) for use with single photon emission computed tomography (SPECT) imaging, for the detection of dopamine transporters (DaT) ...

Thanks to a new diagnostic imaging technique, physicians now have an objective test to evaluate patients for parkinsonian syndromes, such as Parkinson's disease. Northwestern Memorial Hospital is ...

ST. LOUIS, April 05, 2022 (GLOBE NEWSWIRE) -- Curium announced today that its generic version of DaTscan (Ioflupane I 123 Injection) was approved on March 30, 2022, by the U.S. Food and Drug ...

Dec. 4, 2002 (Chicago) - A radiopharmaceutical-imaging agent - ioflupane (I123-FP-CIT) - used with single photon emission computed tomography (SPECT) is "98% accurate" for early diagnosis of Parkinson ...

DaTscan (ioflupane I 123 injection; GE Healthcare) was found to improve a physician’s ability to definitively diagnose patients with dementia with Lewy bodies (DLB) and increase their confidence in ...

The Parkinson’s Progression Markers Initiative (PPMI) was launched in July with hopes of identifying a biomarker, or set of markers, that tracks the natural course of Parkinson disease in 400 newly ...

This supplement to The American Journal of Managed Care summarizes proceedings from a roundtable meeting that was conducted to discuss the diagnosis of Parkinson’s disease and distinguish clinical ...